1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > Europe Nuclear Medicine Market – Trends And Forecasts (2015-2020)

The Europe Nuclear Medicine Market is expected to reach USD 4,660 million by the end of 2020 growing at a CAGR of around 10% from 2015 to 2020. Nuclear Medicine utilizes the radioisotope for application in diagnosis and treatment of diseases. The drugs containing radionuclides are said to be Radiopharmaceuticals. The uses in Radiological imaging include Magnetic Resonance Imaging (MRI), Computerized tomography (CT), Positron Emission Tomography (PET) and Single Proton Emission Tomography (SPECT).

The Nuclear Medicine for diagnostic purposes have gained a huge popularity in Europe. There have been increased use of SPECT, PET, CT, MRI for diagnosis of cardiac diseases, Brain diseases, Cancer and many others.

Nuclear medicine is being used for therapeutic purposes for treatment of Alzheimer’s disease, coronary heart diseases, bone metastasis and many other cancers. In Europe, treatment for thyrotoxicosis through Nuclear medicine shares a large proportion in Nuclear medicine therapeutics market. Advancement in Diagnostic imaging is bringing in more use of Nuclear medicine. Nuclear Medicine for therapeutic purposes is being used for treatment of cancers, different medical conditions affecting thyroid gland, and scar – tissue removal.

The increasing incidence and prevalence of Cancer, Thyroidal diseases, endocrinal diseases and cardiac Ailments, rise in applications of SPECT and PET with advancement of technology and growing awareness amongst physicians and public awareness for better healthcare are key factors driving the growth of Nuclear medicine market. However, Short half-life of Radiopharmaceuticals, high capital investment required for development, stringent regulatory guidelines are factors turning out to be restraints for this market.

The Europe Nuclear Medicine Market have been segmented based on, type and application. The segmentation based on type of Product have been segmented based on diagnostic market and therapeutic market, wherein, the Diagnostics market have been further subdivided into SPECT radioisotopes that include Technetium-993, Thallium-201, Iodine-123, Gallium and PET radioisotopes that include Rubidium-82, Flourine-18 and the therapeutics category have been segmented into Alpha emitters (Radium-223), Beta Emitters(includes Iodine-131, Samarium-153, Lutetium-177, Yttrium-90) and Brachytherapy (includes iodine-125, Cesium-131, Palladium-103, & Iridium-192). The segmentation based on application have been similarly subdivided based on diagnostic and therapeutic application. The Diagnostic application includes the application of SPECT and PET in Cardiology, Neurology, Oncology and others. The therapeutic applications includes application in Oncology, Thyroid, Endocrinology and various other therapeutic areas.

The Europe geographical segmentation have been categorized into United Kingdom, German, France, Scandinavia, Italy, Spain and Benelux. Driving factor for the market in Europe is the umbrella organization for Nuclear Medicine, European Association for Nuclear Medicine (EANM) in Europe, which stands ready for political follow up and professional input to guarantee patient care and patient safety throughout Europe. Further upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications. France, UK and Germany leads in Europe, when it comes to usage of nuclear medicine.

Currently, the segment of diagnostics holds the largest share in Nuclear Medicine Market in which again SPECT has the largest share. In the segmentation based on type, the Beta Emitters hold the largest share. The increasing imaging technologies, potential radioisotopes in pipeline, increasing neurological applications and cyclotron based production are becoming key opportunities for growth of Nuclear Medicine Market. The Key Players in this Nuclear Medicine market are Mallinckrodt, Lantheus Medical Imaging, IBA Group, Triad Isotope, Siemens Healthcare, NTP Radioisotopes, Cardinal Health, GE Healthcare, Nordion, Inc., and Fujifilm Holding Corporation.

Table Of Contents

Europe Nuclear Medicine Market - Trends And Forecasts (2015-2020)
Study deliverables
Market Definition
Sizing Units
Base Currency
Review and Forecast period years
General Study Assumptions
Research Methodology
Analysis Methodology
Econometric Forecast Model
Research Assumptions
Executive Summary
Key Inferences
Market Overview and Industry trends
Current Market Senario
Nuclear Medicine Applications
Technology Overview
New Developments
Industry Value chain analysis
product Life cycle analysis
Product Benchmarking
Investment Analysis
Porter's Five Forces
Bargaining Power of Suppliers
Bargaining Power of Consumers
Threat to new entrants
Threat to substitute products and services
Competitive Rivalry within the industry
Drivers, Restraints, Opportunities, and challenges Analysis
Market Drivers
Increasing incidents of Cancer and Cardiac Ailments
Increasing SPECT and PET applications
Growing awareness amongst Physicians and Public usage of Advanced healthcare facilities
Market Restraints
Short half-life of Radiopharmaceuticals
High Capital Investment
Regulatory Guidelines
Increasing Imaging Technologies
Potential Radioisotopes in Pipeline
Increasing Neurological Applications
Cyclotron Based Production
Shutdown of Nuclear Reactors
Europe Nuclear Medicine Market Segmentation
Nuclear Medicine Market, by Type of Product
Diagnostic Market
Spect Radioisotopes
Technetium-99m (TC-99m)
Thallium-201 (Tl-201)
Iodine (I-123)
Gallium-67 (Ga-67)
PET Radioisoti
Therapeutics Market
Alpha Emitters
Radium-223 (Ra-223)
Beta Emitters
Iodine-131 (I-131)
Samarium-153 (Sm-153)
Rhenium-186 (Re-186)
Lutetium-177 (Lu-177)
Yttrium-90 (Y-90)
Iodine-125 (I-125)
Cesium-131 (Cs-131)
Nuclear Medicine Market, by Application
Market segmentation by Geography - Europe Share and forecast
Spain and Portugal
Competitive Landscape
Merger and acquisition analysis
New Product Launches
Agreements, Collaborations and Parterships
Key Vendor Analysis
Lantheus Medical Imaging
IBA Group
Triad Isotope
Siemens Healthcare
NTP Radioisotopes
Cardinal Health, Inc.
GE Healthcare
Nordion, Inc.
Fujifilm Holding Corporation
Analyst outlook for Investment opportunities
Future Outlook of the market

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Global Nuclear Medicine Market

Global Nuclear Medicine Market

  • $ 4 250
  • Industry report
  • October 2016
  • by Mordor Intelligence LLP

The global nuclear medicines market is expected to reach USD 17,600 million by the end of 2020, growing at a CAGR of around 12.29% from 2015 to 2020. Nuclear medicine utilizes the radioisotope for application ...

Global Nuclear Medicine Diagnostics Market (SPECT and PET ) - Analysis and Forecasts (2015-2020)

Global Nuclear Medicine Diagnostics Market (SPECT and PET ) - Analysis and Forecasts (2015-2020)

  • $ 4 250
  • Industry report
  • August 2016
  • by Mordor Intelligence LLP

The Global Nuclear Medicine Market is expected to reach USD 17,600 million by the end of 2019 growing at a CAGR of around 12.29% from 2014 to 2019. Nuclear Medicine utilizes the radioisotope for application ...

Asia-Pacific Nuclear Medicine Market – Trends And Forecasts (2015-2020)

Asia-Pacific Nuclear Medicine Market – Trends And Forecasts (2015-2020)

  • $ 3 850
  • Industry report
  • August 2016
  • by Mordor Intelligence LLP

The Asia-Pacific nuclear medicine market is estimated at USD 495 million in 2015 and is forecasted to reach USD 910 million by the end of 2020 growing at a CAGR of around 10.7% in the forecast period 2015 ...


Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.